Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Tolerability of BAK-free Latanoprost in Glaucoma
NCT03331770Phase 4Completed
- Sponsor
- Laboratorios Poen
- Start
- Jan 2017
- Primary completion
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of latanoprost ophthalmic solution 0.005% (TearClear TC-002) in primary open-angle glaucoma (POAG) and Pseudoexfoliation Glaucoma (PEG), sponsored by Laboratorios Poen. Primary endpoint: Intraocular pressure at 12 weeks. Started Jan 2017; status: completed.
02
Drugs
latanoprost ophthalmic solution 0.005% (TearClear TC-002)
03
Conditions
primary open-angle glaucoma (POAG)Pseudoexfoliation Glaucoma (PEG)
Beyond the preview
Go deeper on NCT03331770.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03331770.